Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Lai

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Biorxiv : the Preprint Server for Biology|November 26, 2025
<i>RRAS</i> and <i>RRAS2</i> mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236Alexander J Pfeil, Tom Zhang, Ryan Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2026
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236Alexander J Pfeil, Tom Zhang, Ryan Cheng, et al.
BMC Pulmonary Medicine|November 14, 2023
Comparison of the 12-month impact of COVID-19 and SARS on physiological capacity and health-related quality of lifeKen Ka Pang Chan, Susanna So Shan Ng, Grace Chung Yan Lui, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Biorxiv : the Preprint Server for Biology|November 26, 2025
<i>RRAS</i> and <i>RRAS2</i> mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236Alexander J Pfeil, Tom Zhang, Ryan Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2026
RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236Alexander J Pfeil, Tom Zhang, Ryan Cheng, et al.
BMC Pulmonary Medicine|November 14, 2023
Comparison of the 12-month impact of COVID-19 and SARS on physiological capacity and health-related quality of lifeKen Ka Pang Chan, Susanna So Shan Ng, Grace Chung Yan Lui, et al.
Pageof 4